In this project, the Barozzi’s research group will investigate non-genetic mechanisms driving hormone-dependent breast cancers to slowly adapt to hormone therapies.
Breast cancer is the most common cancer among women. About two-thirds of these cancers are sensitive to hormones and can be treated with hormone-blocking therapies. These treatments often work well at first, but for about 1 in 5 women, the tumor returns within 10 years and becomes much harder to treat.
The project will combine single-cell multi-omics techniques and pooled CRISPR-Cas9 screens, with advanced computational analyses and machine-learning techniques, with the goal of identifying regulators of cancer cell heterogeneity and plasticity, whose perturbation affect the ability of the cells to adapt to the treatment. This has the potential to pinpoint novel combination therapies to stop breast cancer cells to evolve resistance.
Projekt: Manipulating drivers of transcriptional heterogeneity
Grant-DOI: 10.55776/PAT7184624